By Elaine Rigoli
Tampa, Fla., July 19 - Lux Biosciences, Inc. announced that the company has increased its series A venture round by $13 million, bringing Lux's total series A round, first announced May 25, to $49 million.
The round added a new investor, Prospect Venture Partners, which is participating with $12 million as an equal partner to previously announced investors in the round, HBM Partners AG, Novo A/S and SV Life Sciences.
Also joining the round is SV Life Sciences' publicly traded fund, International Biotechnology Trust plc.
As part of the transaction, David Schnell, a managing director of Prospect Venture Partners, has joined the Lux board of directors.
Lux Biosciences is a privately held biotechnology company located in Jersey City, N.J.
| Issuer: | Lux Biosciences, Inc.
|
| Issue: | Series A financing
|
| Amount: | $49 million
|
| Investors: | Prospect Venture Partners, HBM Partners AG, Novo A/S, SV Life Sciences and International Biotechnology Trust plc
|
| Announcement date: | July 19
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
